Literature DB >> 22138282

[Pharmaceutical prescription in primary care. SESPAS report 2012].

Gabriel Sanfélix-Gimeno1, Salvador Peiró, Ricard Meneu.   

Abstract

In 2010, the Spanish National Health Service (NHS) paid for 958 million prescriptions. Given the massive population exposure to medication, the risks associated with drug consumption are highly significant from the perspective of public health. Areas requiring improvement in primary care prescription include overtreatment of patients in low risk situations, undertreatment of those in whom medication is indicated, poor patient information, polymedication, self-medication and the appreciable percentage of preventable adverse effects. Surprisingly, most of the pharmaceutical strategies in the NHS have not aimed to address these problems but have instead concentrated on reducing pharmaceutical expenditure, which is not a problem of pharmaceutical expenditure per se but is rather a consequence of "the problems" of prescription (and of the regulation and management of pharmaceutical services). Some key elements to improve this situation include more integrated healthcare, the development of electronic medical records systems, overall strategies to improve safety, and reducing the role of the pharmaceutical industry. Macro strategies include creating an agency able to objectively assess the additional value provided by a new drug and its additional cost, price fixing in line with cost-effectiveness, and exclusion of drugs with little or no added value from coverage, etc. Managing prescription involves the development of longitudinal patient care programs that incorporate clinical actions from different professionals, including whom to treat, how much to treat and how to treat.
Copyright © 2011 SESPAS. Published by Elsevier Espana. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22138282     DOI: 10.1016/j.gaceta.2011.09.015

Source DB:  PubMed          Journal:  Gac Sanit        ISSN: 0213-9111            Impact factor:   2.139


  5 in total

1.  Multimorbidity, polypharmacy, referrals, and adverse drug events: are we doing things well?

Authors:  Amaia Calderón-Larrañaga; Beatriz Poblador-Plou; Francisca González-Rubio; Luis Andrés Gimeno-Feliu; José María Abad-Díez; Alexandra Prados-Torres
Journal:  Br J Gen Pract       Date:  2012-12       Impact factor: 5.386

2.  Study CAMBIMED: Effects of changes in medication appearance on safety of antihypertensive and hypolipidemic treatments in chronic patients older than 65 years in primary health care.

Authors:  Jesús Mario Arancon-Monge; Alicia de-Castro-Cuenca; Ángel Serrano-Vázquez; Luz Campos-Díaz; Montserrat Díaz-Eraso; Isabel Del Cura-González; Elena Polentinos-Castro; Ricardo Rodríguez-Barrientos
Journal:  BMC Public Health       Date:  2015-03-04       Impact factor: 3.295

Review 3.  Health promotion or pharmacological treatment for chronic diseases?

Authors:  M F Allam; Ortiz Arjona
Journal:  J Prev Med Hyg       Date:  2013-03

4.  [Effects of changing the appearance of medications in safety and adherence in chronic patients over 65 years of age in primary care. CAMBIMED Study].

Authors:  Jesús Mario Arancón-Monge; Alicia de Castro-Cuenca; Ángel Serrano-Vázquez; Luz Campos-Díaz; Ricardo Rodríguez Barrientos; Isabel Del Cura-González
Journal:  Aten Primaria       Date:  2019-08-31       Impact factor: 1.137

5.  [Design and piloting of a structured service medication dispensing process].

Authors:  Raquel Abaurre; Pilar García-Delgado; M Dolores Maurandi; Cristóbal Arrebola; Miguel Ángel Gastelurrutia; Fernando Martínez-Martínez
Journal:  Aten Primaria       Date:  2014-04-14       Impact factor: 1.137

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.